PETITION UPDATE
Significant revelations
10 Feb 2025
Significant revelations from a German investigative journalist
In
a detailed article in German, Martin Rücker, part of RiffReporter, presented some extraordinary findings from his investigation of the Cochrane story. He reported that Cochrane sources have said the decision to abandon the replacement review process was made, not on the grounds stated by Cochrane, but in an attempt to avoid dealing with controversy.
"The Cochrane organization told RiffReporter that the decision was made at a meeting of the Governing Board, Cochrane's highest governing body, which took place in Prague from 7-9 September [2024]".
He refers to a controversy where a Cochrane review appeared to support the idea that masks are not useful in the control of Covid-19 (for more on the mask review, see
here).
Rücker continued:
"According to people involved, [the mask controversy] created a certain amount of conflict fatigue.
A foreseeable, yet again fierce, further conflict over a new ME/CFS review did not seem very attractive. This attitude, the complaints from ME/CFS patients that had been piling up for a long time, plus the constant fire from Graded Exercise advocates who wanted to prevent a review update anyway - all of this combined apparently led to the decision to abandon the project."
Rücker further said that pressure from exercise therapy supporters including Peter White and Michael Sharpe, both PACE trial principal investigators, and both having long term financial conflicts of interest in their paid role advising health insurance companies, and from Paul Garner had been influencing Cochrane's decision-making.
David Tuller in The Sick Times
Another investigative journalist, David Tuller, published a great article in The Sick Times
'"Really pissed off": Cochrane receives backlash from advocates and experts after abandoning ME/CFS review'.
His article provides an accessible summary of the events for people new to this saga. It includes comments from two of the writing team Cochrane had appointed to update the review:
Todd Davenport: "This experience has really showed me the extent of the political games behind this supposedly objective process of trying to synthesize studies"
Mary Dimmock: "We put a lot of work into doing this in good faith, and they just pulled it with no consideration for the patients"
Tuller concluded ".. it appears that Cochrane’s actions are, from its perspective, irreversible. But unless it acts quickly to clean up this mess, the long-term damage to its reputation could be irreversible as well."
Tuller has also
written about a letter submitted to the BMJ, a medical journal, by Professor Jonathan Edwards. Professor Edwards notes that it is clear that his previous concerns about Cochrane's conflicts of interests are well founded. He wrote
"This really is a shocking story. Whoever was responsible for the decision to block the project should be required to publicly explain their actions. Otherwise, Cochrane’s reputation is worthless."
Science for ME's deadline for Cochrane looms
Two weeks ago, the Science for ME committee submitted
a complaint to Cochrane about its failure to follow its complaint processes. Our complaint noted that we still have not had any meaningful response to the complaints we submitted in October 2023. We informed Cochrane that if we did not receive an appropriate response from them by 14 February 2025, we would have to notify various authorities of the failure of Cochrane's complaint system.
More complaints sent to Cochrane
Last week, the Science for ME committee submitted
a detailed set of five new complaints with supporting evidence.
Complaints 1 to 4 focussed on the December 2024 relabelling of the 2019 Larun et al review as a 2024 review. An effect of the relabelling was to make previous critical comments that had been linked to the 2019 appear as though they had been addressed in the new version. These comments now appear with a note:
"Note: This comment relates to a previous version of this review:"
Given that the 2019 review is completely identical to the 2024 and that there was no response to the comments, the comments clearly apply equally to the 2024 version.
The relabelling of the review creates the false impression of a new review update that has considered recent research and addressed previous comments, just in time for ME/CFS guideline development processes in Australia and the Netherlands.
Complaint 5 addressed Cochrane's decision-making processes.
We concluded:..
"We find these actions by Cochrane so clearly indefensible and the arguments so illogical that we can only conclude that senior editors and Trustees have given in to pressure from proponents of exercise therapy for ME/CFS. We ask Cochrane to take the following actions in order to restore its credibility and avoid further harm to patients."
Actions requested include removal of the 2024 version; an editorial note saying the review is outdated and should not be used for clinical care; standing firm against pressure from exercise proponents with vested interests; and re-considering the decision not to withdraw the 2019 review.
Thanks
We appreciate the journalists investigating Cochrane's actions; their articles are crucial in bringing awareness. We also appreciate all of you who are supporting the campaign. It has been heartening to see the number of supporters grow so rapidly over recent weeks.
We continue to be moved by comments posted on the petition. They help us to remain committed to working towards the withdrawal of the Larun et al review.